Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.

Trial Details

NCT ID
NCT03379909
Phase
PHASE2
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Metformin
Locations (sample)
  • Nijmegen, Gelderland, Netherlands|51.8425,5.85278
  • Rotterdam, South Holland, Netherlands|51.9225,4.47917
  • Amsterdam, Netherlands|52.37403,4.88969

Key Eligibility Criteria

  • Age \> 18 years.
  • Patients with primary or recurrent suspectedTa or T1, G1 or G2 (low grade) urothelial carcinoma of the bladder with no suspicion of carcinoma in situ.
  • Patients must have at least 1 lesion but no more than 5.
  • There must be one index lesion measuring between 0.5 and 1.0 cm in its greatest dimension.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →